1. HBW Insight
  2. >>Beauty
  3. >>Business

GSK Divesting Horlicks Nutritional Business, Investing In OTC Production

 
• By Malcolm Spicer

Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.

GlaxoSmithKline PLC's solo flight in the consumer health space features more of the investing and divesting it did while operating the business as the majority owner of a joint venture.

GSK's latest consumer health investment was a $36m upgrade to a Canadian facility, where by mid-2019 it will begin making OTC Voltaren topical gel products formulated to reduce inflammation and help relieve pain. The UK pharma on Sept

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Coty Lowers FY25 Forecast On Tariff Uncertainty, Inventory Reductions, But Expects Sunnier Days In FY26

 
• By Eileen Francis

Coty lowers its revenue and profit outlook for FY25, though it believes FY26 will be a better year thanks to a return of ‘blockbuster’ product launches, market expansion and mitigation strategies for current economic uncertainties.

Estee Lauder Lowers FY 2025 Outlook, Expects Positive Results FY 2026 On ‘Beauty Reimagined’

 
• By Eileen Francis

The Estee Lauder Companies reported a 10% drop in reported sales during its fiscal third quarter presentation on a 28% decline in travel retail organic sales. The firm, which lowered its FY 2025 sales expectations, says it expects positive growth in FY 2026.

Coty’s Next Phase Of ‘All-In To Win’ Strategy Should Generate $130M Savings

 
• By Eileen Francis

Coty’s ‘All-in to Win’ program enters the next phase, which sets aggressive savings over the next two years in part by simplifying and scaling its operating model, in addition to boosting its innovation impact.

P&G: Innovation, Pricing ‘Short-Term Levers’ For Tariffs Adding Up To $1.5Bn In Costs Annually

 
• By Eileen Francis

The Procter & Gamble Company is working to mitigate the impact of tariffs, which will add up to $1.5bn in costs annually. The firm has lowered its fiscal 2025 outlook.

More from Beauty

Fragrance Industry Unification Hedges Against Tariff Impact – Experts

 
• By Eileen Francis

Fragrance companies and suppliers can draft contracts that ensure the cost burden of tariffs is shared, says attorney David Morrell of law firm Jones Day, during a recent panel discussion, ‘Tariffs in Motion: Insight for the Fragrance Industry.”

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.